Adverse Event Reporting and Causality Assessment
A 54-year-old woman started allopurinol 300 mg daily 3 weeks ago for gout. She presents with fever, a widespread pruritic maculopapular rash, facial swelling, and eosinophilia (1.2 x 10^9/L). Liver enzymes are elevated (ALT 180 U/L, baseline 25 U/L), and she has a creatinine rise from 0.8 to 1.6 mg/dL. She also started hydrochlorothiazide 2 weeks ago for hypertension. She has no prior drug allergies. The prescriber suspects a viral exanthem and plans to continue allopurinol. The pharmacist is asked to assess the reaction and decide on reporting.
1. Assess the likelihood that this is an allopurinol hypersensitivity reaction and compare it with alternative explanations.
Read the worked answer
Clinical picture. Fever, rash, facial swelling, eosinophilia, hepatitis, and acute kidney injury beginning 3 weeks after starting allopurinol is a classic presentation of allopurinol hypersensitivity syndrome (AHS), also called DRESS (drug reaction with eosinophilia and systemic symptoms). The timing fits: AHS typically occurs 2-8 weeks after initiation. The presence of eosinophilia plus hepatic and renal involvement strongly supports a systemic drug reaction rather than a simple exanthem.
Risk factors. The 300 mg dose is relatively high for a patient with renal impairment; AHS risk is dose-dependent and higher with renal impairment. The HLA-B*58:01 allele is a strong risk factor in certain populations (notably Han Chinese, Thai, and Korean), but testing status is unknown here.
Alternatives.
- Viral exanthem: possible but does not explain eosinophilia, hepatitis, and rising creatinine.
- Hydrochlorothiazide: can cause photosensitivity, rash, and rarely DRESS, and was started 2 weeks ago, so it is a plausible alternative or contributor. However, the broader systemic features and timing align better with allopurinol.
- Infection: fever and rash could reflect infection, but eosinophilia and organ involvement favor drug reaction.
- Gout flare: can cause fever but not this rash and eosinophilia.
Assessment. Allopurinol is the most likely culprit, with hydrochlorothiazide as a possible contributor. The reaction is serious and potentially life-threatening. Allopurinol should be stopped immediately, not continued. The prescriber's plan to continue is unsafe and should be challenged with the evidence.
2. What immediate management recommendations should the pharmacist make?
Read the worked answer
Stop the suspected drug. Discontinue allopurinol immediately. Also consider stopping hydrochlorothiazide, since it is a possible contributor and can be replaced with another antihypertensive.
Supportive care.
- Assess airway and facial swelling; angioedema can progress. Ensure emergency evaluation.
- Fluid and electrolyte management for acute kidney injury; monitor urine output and creatinine daily.
- Skin care; avoid unnecessary antibiotics unless infection is confirmed.
- Antihistamines for pruritus; systemic corticosteroids are often used in DRESS but the decision belongs to the treating clinician.
Monitoring.
- Liver enzymes and renal function daily until improving.
- Complete blood count with differential for eosinophilia and for cytopenias.
- Temperature and vital signs.
- Watch for myocarditis, pneumonitis, and thyroid involvement, which can occur in DRESS.
Avoid rechallenge. Allopurinol must not be restarted. Document the allergy clearly. If urate-lowering therapy is needed later, an alternative such as febuxostat may be considered, with caution and specialist input.
Communication. Discuss the assessment with the prescriber, explain why continuation is unsafe, and document the recommendation and response. Escalate if the prescriber does not act.
3. How should this case be reported, and what causality and severity descriptors would you use?
Read the worked answer
Reporting. This is a serious adverse drug reaction (hospitalization or risk of death, organ involvement). It should be reported to the national pharmacovigilance authority (for example, the NHRA or equivalent national reporting system) and to the manufacturer. Report all suspected drugs, including hydrochlorothiazide, since it is a possible contributor. Include the timeline, dose, indication, concomitant drugs, laboratory values, and outcome.
Causality assessment (WHO-UMC scale). The reaction is 'probable' or 'probable/likely' for allopurinol: it began within a plausible time frame after initiation, the clinical picture is a recognized pattern, and there is a reasonable response to withdrawal (expected). It is not 'certain' because rechallenge is not ethically permissible and because hydrochlorothiazide is a confounder. For hydrochlorothiazide, causality is 'possible.'
Severity. Serious, potentially life-threatening. Use a severity scale such as the Hartwig or WHO toxicity grading; this would be grade 4 (life-threatening) given organ involvement.
Preventability. Possibly preventable: a lower starting dose in renal impairment and HLA-B*58:01 screening in at-risk populations could have reduced risk. Document the preventability assessment.
Follow-up. Track the outcome and update the report if new information emerges. Feed the case into local medication-safety review and consider a safety alert if a pattern emerges.